In June 2026, Helus Pharma reported that enrollment in its APPROACH Phase 3 trial of HLP003 for adjunctive treatment of major ...
In early March 2026, Helus Pharma, a Cybin subsidiary, reported positive topline Phase 2 results for HLP004 as an adjunctive intramuscular treatment for adults with moderate-to-severe generalized ...
- Interim readout shows rapid, robust, and clinically significant reduction of depression symptoms three weeks after a single 12mg dose, with an unprecedented mean -14 point Montgomery-Asberg ...
USA News Group News Commentary, In drug development, enrollment is the quiet variable that decides whether a promising therapy ever reaches a ...
Shares of Cybin (NYSEMKT: CYBN), a pre-commercial drugmaker focused on developing psychedelics, fell more than 17% this morning. The company reported success with CYB003, a novel psilocybin analog, ...
Cybin Inc. CYBN announced that it has received approval from an independent ethics committee in the Netherlands to begin the first in-human dosing of its proprietary deuterated N, N-dimethyltryptamine ...
Psychedelics company Cybin Inc. CYBN announced an overnight marketed public offering of its units and confirmed its set pricing on an aggregate 24,264,706 Cybin units, at $0.34 each, for aggregate ...
- Combination creates the largest intellectual property portfolio in the psychedelic drug development sector with 28 patents granted and 158 patents pending - - Creates strong synergies by combining ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results